Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017, Article ID 7063859, 7 pages
https://doi.org/10.1155/2017/7063859
Research Article

Yin-Cold or Yang-Heat Syndrome Type of Traditional Chinese Medicine Was Associated with the Epidermal Growth Factor Receptor Gene Status in Non-Small Cell Lung Cancer Patients: Confirmation of a TCM Concept

1Oncology Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China
2Division of Speech & Hearing Sciences, The University of Hong Kong, Pokfulam, Hong Kong
3Department of Big Medical Data, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China

Correspondence should be addressed to Hai-bo Zhang; moc.nuyila@hzobiah

Received 28 July 2016; Accepted 7 December 2016; Published 22 January 2017

Academic Editor: Omer Kucuk

Copyright © 2017 Yan-juan Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Z. Chen, C. M. Fillmore, P. S. Hammerman, C. F. Kim, and K. K. Wong, “Non-small-cell lung cancers: a heterogeneous set of diseases,” Nature Reviews Cancer, vol. 14, pp. 535–546, 2014. View at Publisher · View at Google Scholar
  2. T. Mitsudomi, S. Morita, Y. Yatabe et al., “Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial,” The Lancet Oncology, vol. 11, no. 2, pp. 121–128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Zhou, Y.-L. Wu, G. Chen et al., “Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study,” The Lancet Oncology, vol. 12, no. 8, pp. 735–742, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Maemondo, A. Inoue, K. Kobayashi et al., “Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR,” The New England Journal of Medicine, vol. 362, no. 25, pp. 2380–2388, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Rosell, E. Carcereny, R. Gervais et al., “Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial,” The Lancet Oncology, vol. 13, no. 3, pp. 239–246, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Kay Garcia, J. Mcquade, R. Haddad et al., “Systematic review of acupuncture in cancer care: a synthesis of the evidence,” Journal of Clinical Oncology, vol. 31, no. 7, pp. 952–960, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Ying-Jie, H. Min-Na, S. Yi-Yu, C. Jun, L. Xiao-Jiang, and C. Liang, “Clinical study of tarceva in combination with Xiaoyantang plus-minus prescriptions in treatment of non-small cell lung cancer,” Chinese Clinical Oncology, vol. 14, pp. 622–624, 2009 (Chinese). View at Google Scholar
  8. D. Jian, “Clinical observation of huachansu injection combined with gefitinib in the treatment of late stage non-small cell lung cancer,” Chinese Journal of Modern Drug Application, vol. 4, pp. 76–78, 2007 (Chinese). View at Google Scholar
  9. S. Qing-Hua and C. Gao-Feng, “Clinical observation of kanglaite injection combined with gefitinib in the treatment of non-small cell lung cancer with EGFR positive in medium or late stage,” Chinese Manipulation & Rehabilitation Medicine, vol. 4, pp. 76–78, 2013 (Chinese). View at Google Scholar
  10. C. Xiao, L. Liang, Z. Hua et al., “Comparison analysis of differentially expressed plasma proteins in patients with advanced non-small cell lung cancer treated with Kangai Fuzheng decoction and gefitinib,” Modern Journal of Integrated Traditional Chinese, vol. 22, pp. 1487–1490, 2013. View at Google Scholar
  11. L. Yi-tang, “Clinical research on treating NSCLC in TCM plus molecular targeted medicine,” Clinical Journal of Chinese Medicine, vol. 5, pp. 94–95, 2013 (Chinese). View at Google Scholar
  12. S. Li, A. Lü, and H. Jia, “Therapeutic actions of the Chinese herbal formulae with cold and heat properties and their effects on ultrastructures of synoviocytes in rats of the collagen-induced arthritis,” Journal of Traditional Chinese Medicine, vol. 22, no. 4, pp. 296–302, 2002. View at Google Scholar · View at Scopus
  13. N. Thatcher, A. Chang, P. Parikh et al., “Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer),” Lancet, vol. 366, no. 9496, pp. 1527–1537, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. F. A. Shepherd, J. R. Pereira, T. Ciuleanu et al., “Erlotinib in previously treated non-small-cell lung cancer,” The New England Journal of Medicine, vol. 353, no. 2, pp. 123–132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. J. G. Paez, P. A. Jänne, J. C. Lee et al., “EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy,” Science, vol. 304, no. 5676, pp. 1497–1500, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. T. J. Lynch, D. W. Bell, R. Sordella et al., “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib,” New England Journal of Medicine, vol. 350, no. 21, pp. 2129–2139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. T. S. Mok, Y.-L. Wu, S. Thongprasert et al., “Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma,” New England Journal of Medicine, vol. 361, no. 10, pp. 947–957, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Savas, B. Hughes, and B. Solomon, “Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer,” Journal of Thoracic Disease, vol. 5, no. 5, pp. S579–S592, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. L. V. Sequist, J. C.-H. Yang, N. Yamamoto et al., “Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations,” Journal of Clinical Oncology, vol. 31, no. 27, pp. 3327–3334, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. S.-W. Hwang, H.-S. Han, K. Y. Lim, and J.-Y. Han, “Drug interaction between complementary herbal medicines and gefitinib,” Journal of Thoracic Oncology, vol. 3, no. 8, pp. 942–943, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. Z. Gao, S. Li, Q. Shang et al., “Complex networks approach for analyzing the correlation of traditional chinese medicine syndrome evolvement and cardiovascular events in patients with stable coronary heart disease,” Evidence-based Complementary and Alternative Medicine, vol. 2015, Article ID 824850, 6 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus